Thyroid Cancer

Company gets European marketing approval of Thyrogen for thyroid tissue ablation

Published in Gene Therapy Weekly, March 31st, 2005

Genzyme Corp. (GENZ) announced that the European Commission has approved the company's marketing application for a therapeutic indication for Thyrogen (thyrotropin alfa for injection) when used in combination with radioiodine.

The new label permits the product's use in the European Union for the ablation of remnant thyroid tissue, a procedure that patients commonly undergo when being treated for thyroid cancer.

Genzyme is also seeking to add the ablation indication to the product's U.S. label and expects regulatory action on its submission in the second half of this year. Approximately 35,000 ablation procedures are performed annually in the United...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry